---
title: "Revolution Medicines, Inc. (RVMD.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/RVMD.US.md"
symbol: "RVMD.US"
name: "Revolution Medicines, Inc."
industry: "Biotechnology"
datetime: "2026-05-19T20:27:02.104Z"
locales:
  - [en](https://longbridge.com/en/quote/RVMD.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/RVMD.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/RVMD.US.md)
---

# Revolution Medicines, Inc. (RVMD.US)

## Company Overview

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.revmed.com](https://www.revmed.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -21.85 | 507 | - | - | - |
| PB | 19.98 | 417 | 12.10 | 8.37 | 3.60 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **21**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 17 | 81% |
| Overweight | 4 | 19% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 147.30 |
| Highest Target | 263.00 |
| Lowest Target | 116.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/RVMD.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/RVMD.US/norm.md)
- [Related News](https://longbridge.com/en/quote/RVMD.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/RVMD.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**